The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with ...

Wedbush reissued their outperform rating on shares of Black Diamond Therapeutics (NASDAQ:BDTX – Free Report) in a research ...

Investment analysts at Wedbush upped their Q1 2025 EPS estimates for Black Diamond Therapeutics in a research note issued to investors on Wednesday, March 19th. Wedbush analyst R. Driscoll now expects ...

Black Diamond said Servier will develop and commercialize BDTX-4933, a small molecule designed by the Cambridge, Mass., company to address unmet medical needs in RAF/RAS-mutant solid tumors.

Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an ...

The black diamonds that are found on tape measures have been a source of confusion for many - but it turns out that they ...

This recall involves all BD Vision Harnesses. This lightweight harness is designed for technical alpine and ice climbs. All ...

Black Diamond Equipment has announced a recall of all BD Vision Harnesses due to a potential fall hazard. This action is ...

The strategic worldwide licensing agreement grants Servier the rights to develop and commercialize BDTX-4933, a therapy currently in Phase 1 development. Under the terms of the deal, Black Diamond ...

Black Diamond Equipment BD Vision harnesses are being recalled due to premature degradation of its construction and materials ...

Servier will be responsible for development and global commercialisation of the therapy for several indications.

A marketing expert reacts to an image of see-through Black Diamond American cheese, claiming it could be a result of ...